Our innovative molecular-based detection tool is complementary to HPV vaccination.
Screening remains crucial even for vaccinated women, as vaccines don’t protect against all HPV types
In countries with high vaccination coverage (over 80%), HPV infections responsible for most cervical cancers have decreased by 87–97%. Our advanced molecular detection tool complements vaccination efforts and plays a crucial role in the prevention and early detection of cervical cancer.
Crucial early detection for both vaccinated and unvaccinated women
While HPV vaccination has dramatically reduced cervical cancer risk – comprehensive screening remains essential for women’s health. Our innovative molecular-based detection tool:
Provides crucial early detection for both vaccinated and unvaccinated women
Vaccines protect against major HPV types but not all cancer-causing variants
~500,000 new cases globally each year, with significant numbers even in highly vaccinated populations
Complements existing prevention strategies
Works alongside vaccination and traditional screening methods
Helps identify cases that might be missed by conventional approaches
Particularly valuable for regions with lower vaccination rates
Advances precision medicine through molecular-level detection
Transcriptome analysis offers deeper insights into cellular changes
May detect pre-cancerous changes earlier than traditional methods
Supports more personalized treatment approaches
Here’s why our molecular-based detection test is a game-changer:
Early Detection Saves Lives: Our test identifies high-risk HPV infections early, giving you and your doctor time to act.
Precise and Reliable: Advanced molecular technology ensures accurate results, giving you peace of mind.
Complements Vaccination: Even with high vaccination rates, regular screening is essential to protect against possible cases of cervical cancer not covered by vaccination.